Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Nanobiotix (NBTX) Receivables - Other (2019 - 2025)

Nanobiotix has reported Receivables - Other over the past 7 years, most recently at $2.5 million for Q4 2025.

  • For Q4 2025, Receivables - Other fell 21.76% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $2.5 million, down 21.76%, while the annual FY2025 figure was $2.5 million, 21.76% down from the prior year.
  • Receivables - Other for Q4 2025 was $2.5 million at Nanobiotix, down from $3.2 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $3.9 million in Q4 2021 and troughed at $1.5 million in Q4 2023.
  • A 5-year average of $2.8 million and a median of $2.8 million in 2022 define the central range for Receivables - Other.
  • Biggest five-year swings in Receivables - Other: surged 252.29% in 2021 and later tumbled 45.44% in 2023.
  • Year by year, Receivables - Other stood at $3.9 million in 2021, then fell by 27.63% to $2.8 million in 2022, then tumbled by 45.44% to $1.5 million in 2023, then skyrocketed by 108.3% to $3.2 million in 2024, then fell by 21.76% to $2.5 million in 2025.
  • Business Quant data shows Receivables - Other for NBTX at $2.5 million in Q4 2025, $3.2 million in Q4 2024, and $1.5 million in Q4 2023.